Keep up to date
Press release | 19.03.2020
Univercells investit à Jumet pour la production de vaccins à large échelle
Avec une capacité de 15 000 m², ce nouveau site permettra à Univercells d’accélérer le développement et la production commerciale ...
Press release | 18.02.2020
Univercells secures up to €50M investment from KKR platform to speed delivery of manufacturing technologies
Univercells has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment ...
Press release | 03.10.2019
Univercells boosted by EUR 20M European financing to accelerate the delivery of its vaccine portfolio
Financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable ...
Univercells news | 10.07.2019
Univercells expands its development capacity with modular laboratories
400 m² extension will enable the company to pursue the development of its viral vaccines' portfolio addressing global health challenges
Press release | 13.06.2019
Univercells granted $14.3M to deliver affordable measles & rubella vaccines
Univercells announces today second grant from the Bill & Melinda Gates Foundation to develop a cost-effective manufacturing process and proceed ...
Univercells news | 17.04.2019
Introducing the scale-X™ carbo bioreactor system
The scale-X™ carbo is a bench-scale automated cell culture system for expression and concentration of viral drug substance, suited for ...
In the press | 01.04.2019
Reinventing the Biomanufacturing Wheel
Our Product Manager Tania explains the challenges in biologic manufacturing and Univercells' solutions in BioParhm International article
Univercells news | 27.03.2019
Univercells joins the Belgian State Visit to South Korea
Belgian State Visit to Korea - Hugues Bultot, CEO of Univercells, joins the Belgian business delegation to strengthen and further ...
BioProcessing Summit Europe
Bioprocessing Summit Europe brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development, manufacture and quality of antibodies, vaccines and gene therapies.
BIO-Europe® Digital is so much more than scheduled virtual partnering meetings, recorded content, some live sessions and virtual networking opportunities during the week of October 26–29.
ON Helix is fully committed to bring the insights and connections needed to understand innovation in translational research and support R&D companies in their current and future therapeutic and technology developments.